For instance, in the liver, both liraglutide and exenatide improved liver lesions by regulating the TLR4/nuclear factor κB (NF-κB) inflammatory pathway and oxidative stress in T2DM/nonalcoholic fatty liver disease (NAFLD) rats (16, 17). This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.